Supplementary information

Increased risks between Interleukin-10 gene polymorphisms and haplotype and head and neck cancer: a meta-analysis

Yu-Ming Niu[1,4,#], Xin-Ya Du [2,#], Heng-Xing Cai[3,#], Chao Zhang[4], Rui-Xia Yuan[4], Xian-Tao Zeng[1,5], Jie Luo [4,*]

[1] Department of Stomatology, Taihe Hospital, Hubei University of Medicine, 32 South Renmin Road, Shiyan 442000, P.R. China

[2] Department of Stomatology, People's Hospital of New District Longhua Shenzhen, Shenzhen 518109, P.R. China

[3] The State Key Laboratory Breeding Base of Basic Science of Stomatology & Key Laboratory of Oral Biomedicine, Ministry of Education, Department of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University, Luoyu Road 237, Wuhan 430079, P.R. China..

[4] Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, 32 South Renmin Road, Shiyan 442000, P.R. China

[5] Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, 169 Donghu Road, Wuchang District, Wuhan, 430071, P.R. China

Supplementary Tables

Supplementary Table S1: Scale for quality assessment.

Supplementary Table S2: PRISMA 2009 Checklist For this Meta-analysis.

Supplementary Table S3: PRISMA 2009 Flow Diagram.

Supplementary Table S4: Quality assessment based on the Newcastle-Ottawa Scale of studies included in this meta-analysis.

Table S1 Scale for quality assessment.

Criteria	Score
Representativeness of cases	
Consecutive/randomly selected form case population with clearly defined sampling frame	2
Consecutive/randomly selected form case population without clearly defined sampling frame or with extensive	1
Not described	0
Source of controls	
Population- or Healthy-based	2
Hospital-bases	1
Not described	0
Hardy-Weinberg equilibrium in controls	
Hardy-Weinberg equilibrium	2
Hardy-Weinberg disequilibrium	1
Genotyping examination	
Genotyping done under “blinded” condition	1
Unblinded done or not mentioned	0
Association assessment	
Assess association between genotypes and head and neck cancer with appropriate statistics and adjustment for confounders	2
Assess association between genotypes and head and neck cancer with appropriate statistics and without adjustment for confounders	1
Inappropriate statistics used	0

Table S2 PRISMA 2009 Checklist For this Meta-analysis

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	P1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	P3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	P4,5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	P4,5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	P6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	P6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	P6

Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	P6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	P6,7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	P7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	P7, Appendix 1
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	P7,8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	P7,8

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	P8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	P7,8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	P8,9

Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	P9,10,11,12
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	P9,Appendix 2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	P9,10,11,12
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	P9,10,11,12
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	P9,10,11,12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	P9,10,11,12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	P14,15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	P16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	P16,17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	P17

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

Table S3 PRISMA 2009 Flow Diagram



Table S4 Quality assessment based on the Newcastle-Ottawa Scale of studies included in this meta-analysis.

Author	Year	Representativeness of cases	Source of controls	Hardy-Weinberg equilibrium in controls[a]	Genotyping examination blinded	Association assessment	Total[a]
Pratesi	2006	1	2	2,2,2	0	2	7,7,7
Wei	2007	2	2	1,1,1	0	1	6,6,6
Farhat	2008	2	2	1	0	1	6
Yao	2008	2	2	1,2,2	0	1	6,7,7
Vairaktaris	2008	2	2	1	0	1	6
Jeong	2010	2	1	2	0	1	6
Tsai1	2013	2	1	1,1,2	0	2	6,6,7
Tsai2	2014	2	1	1,1,1	0	2	6,6,6
Hsu	2015	2	2	2,2,2	1	1	8,8,8

[a]: the studies of Pratesi et al., Wei Yao Pratesi et al., Tsai1 Pratesi et al., Tsai2 Pratesi et al., and Hsu Pratesi et al. reported three polymorphisms. And the quality score focused on each polymorphism.